TrialCardiovascular diabetology2022

Endotrophin is a risk marker of complications in CANagliflozin cardioVascular Assessment Study (CANVAS): a randomized controlled trial.

Daniel Guldager Kring Rasmussen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.